Investors News Coverage Nov 10, 2020Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Pancreatic Cancer Oct 29, 2020FDA Grants Rafael Pharmaceuticals Orphan Drug Designation for CPI-613® (devimistat) for Treatment of Soft Tissue Sarcoma Oct 27, 2020Rafael Pharmaceuticals Crosses Enrollment of 100th Patient in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML) Oct 20, 2020A New Phase 1 Study Began to Evaluate Rafael Pharmaceuticals' Lead Compound CPI-613®? (devimistat) for Patients With Pancreatic Cancer in Japan Aug 06, 2020Rafael Pharmaceuticals Achieves Target Enrollment of 500 Patients in Pivotal Phase 3 Trial (AVENGER 500) of CPI-613 ® (devimistat) for Patients with Metastatic Pancreatic Cancer Jul 21, 2020Rafael Pharmaceuticals Crosses Midpoint of Enrollment to First Interim Analysis in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML) May 26, 2020Rafael Pharmaceuticals to Present Phase 1 Data on CPI-613® (Devimistat) in Patients with Locally Advanced or Metastatic Pancreatic Cancer at American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program May 08, 2020Devimistat Development Progresses in Relapsed/Refractory Burkitt Lymphoma May 07, 2020Rafael Pharmaceuticals Announces In Vivo Study to Evaluate the Effects of CPI-613® (Devimistat) in Combination with Azacitidine and Venetoclax on Acute Myeloid Leukemia Models May 05, 2020Rafael Pharmaceuticals Enters into Research Collaboration with Roswell Park Comprehensive Cancer Center to Evaluate the Effects of CPI-613® (Devimistat) on Esophageal Cancer 1 2 3 4 5 << < > >>
